BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

N/A
indicator

NIFTY200 Alpha 30

1D
1M
3M
6M
1Y
5Y
empty graph

NIFTY200 Alpha 30 Performance

Day's Range

Low

₹26,164.10

High

₹26,378.65

52 Week Range

Low

₹21,846.40

High

₹26,745.65

Previous Close ₹26,102.70
Day's Range ₹26,164.10 - ₹26,378.65
Open ₹26,175.20
52 Week Range ₹21,846.40 - ₹26,745.65
Volume 46,25,59,623

NIFTY200 Alpha 30 Companies

Company Name LTP (₹) Change (₹) Sector
Bharat Heavy Electricals Ltd. 387.50 Arrow 3.90 (1.02%) Capital Goods
Steel Authority Of India Ltd. 169.23 Arrow -0.65 (-0.38%) Iron & Steel
Vedanta Ltd. 282.00 Arrow 1.60 (0.57%) Non - Ferrous Metals
Hindalco Industries Ltd. 980.40 Arrow 27.20 (2.85%) Non - Ferrous Metals
The Federal Bank Ltd. 330.30 Arrow 2.90 (0.89%) Bank
Ashok Leyland Ltd. 166.12 Arrow 1.77 (1.08%) Automobile & Ancillaries
Cummins India Ltd. 5578.50 Arrow 100.50 (1.83%) Automobile & Ancillaries
Bharat Forge Ltd. 2138.70 Arrow 2.00 (0.09%) Automobile & Ancillaries
Eicher Motors Ltd. 7471.50 Arrow 132.00 (1.80%) Automobile & Ancillaries
Shriram Finance Ltd. 1062.30 Arrow -1.30 (-0.12%) Finance

All Indices

Index Name Market Value 52W High 52W Low
Nifty 50 24430.35 26373.20 22182.55
Nifty IT 27276.45 40301.40 25699.10
Nifty Next 50 72685.6 73141.05 59896.10
NIFTY50 USD Index 8874.1 10443.40 8132.40
Nifty Bank 58291.5 61764.85 49954.85
NIFTY Midcap 100 62471.5 62909.55 52032.85
Nifty 500 23433.95 24144.20 20385.65
Nifty Midcap 50 17863.55 17905.00 14804.55
Nifty 100 25464.45 26975.15 22720.45
Nifty FMCG 50196.35 58485.05 45334.15

Latest News

Jul
6
2026
EQUITY Posted on Jul 6th 2026

Glenmark Pharmaceuticals informs about press release

Glenmark Pharmaceuticals has informed about the launch of Olanzapine for Injection, 10 mg/vial, Single‐Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa® IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
4
2026
EQUITY Posted on Jul 4th 2026

AU Small Finance Bank informs about updates

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Code of Fair Disclosure and Conduct and in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, AU Small Finance Bank has informed that it enclosed the information on record pertaining to its performance in the quarter ended June 30, 2026. A copy of this letter is being uploaded on the website of the Bank at https://www.au.bank.in/investors.

The above information is a part of company’s filings submitted to BSE.
Read More
Jul
3
2026
EQUITY Posted on Jul 3rd 2026

One 97 Communications informs about grant of payment institution license

Further to its disclosure dated January 13, 2026, regarding incorporation of Paytm Europe in Luxembourg, a wholly owned subsidiary of Paytm Cloud Technologies (a wholly owned Indian subsidiary of the Company) and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’). One 97 Communications has informed that Paytm Europe has been informed by CSSF on July 02, 2026 at 08:03 pm (IST) that it has been granted the payment institution licence and also been registered on the payment institutions official list, with effect from July 02, 2026. The licence has been granted in relation to the provision of services namely: (a) execution of payment transactions, including transfers of funds on a payment account with the user’s payment service provider or with another payment service provider: - execution of credit transfers, including standing orders; (b) execution of payment transactions where the funds are covered by a credit line for a payment service user: - execution of credit transfers, including standing orders; and (c) acquiring of payment transactions. The details of the above license as required under the SEBI Listing Regulations read with SEBI Master Circular Nos. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed in Form A. This disclosure will also be hosted on the Company's website: https://ir.paytm.com/.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
2
2026
EQUITY Posted on Jul 2nd 2026

Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A, a wholly owned subsidiary of the company (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
1
2026
EQUITY Posted on Jul 1st 2026

Ashok Leyland informs about press release

Ashok Leyland has informed that it attached a copy of the communication being released to the Press relating to sales figures for the month of June 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Frequently Asked Questions

What is the Previous Close of NT200ALP30 index?

The previous close of NT200ALP30 index is ₹26315.7 as of 2026-07-06.

The total volume of NT200ALP30 index is 461565125.00 as of 2026-07-06.

The percentage change in value of NT200ALP30 index is 0.82% as of 2026-07-06.

The absolute increase in NT200ALP30 index value since the previous trading day is ₹213.0 as of 2026-07-06.

A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.

View More
Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore